Literature DB >> 3933348

Use of peritoneal dialysis in the treatment of patients with renal failure and paraproteinemia.

S J Rosansky, F W Richards.   

Abstract

The effect of alterations in dwell time, dialysate dextrose concentration, and nitroprusside on immunoglobulin removal during peritoneal dialysis and a comparison of plasmapheresis versus peritoneal dialysis on immunoglobulin removal was studied. 1 h of plasmapheresis removed approximately 100 times as much IgG and 50 times as much IgM and IgA as 1 h of peritoneal dialysis. Nitroprusside added to peritoneal dialysate doubled the hourly removal rate of IgG using 1- and 8-hour cycles and increased IgA and IgM removal by 25 and 10%, respectively, using 8-hour cycles. It was estimated that peritoneal dialysis with nitroprusside added to peritoneal dialysate augments intact immunoglobulin clearance (above endogenous clearance) by approximately 10%. We hypothesized that peritoneal dialysis could significantly increase light-chain removal and thereby may be efficacious in the treatment of light chain related amyloid formation and light chain induced renal failure.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933348     DOI: 10.1159/000166963

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  3 in total

1.  Continuous ambulatory peritoneal dialysis in patients with renal failure due to multiple myeloma.

Authors:  Mufazzal Ahmad
Journal:  Int Urol Nephrol       Date:  2007-01-13       Impact factor: 2.370

2.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; A P Maxwell; I Bruce; B G Murphy; C C Doherty
Journal:  Ir J Med Sci       Date:  1993-06       Impact factor: 1.568

Review 3.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; C C Doherty
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.